Chemical–genetic attenuation of focal neocortical seizures

Abstract

Focal epilepsy is commonly pharmacoresistant, and resective surgery is often contraindicated by proximity to eloquent cortex. Many patients have no effective treatment options. Gene therapy allows cell-type specific inhibition of neuronal excitability, but on-demand seizure suppression has only been achieved with optogenetics, which requires invasive light delivery. Here we test a combined chemical–genetic approach to achieve localized suppression of neuronal excitability in a seizure focus, using viral expression of the modified muscarinic receptor hM4D i . hM4D i has no effect in the absence of its selective, normally inactive and orally bioavailable agonist clozapine-N-oxide (CNO). Systemic administration of CNO suppresses focal seizures evoked by two different chemoconvulsants, pilocarpine and picrotoxin. CNO also has a robust anti-seizure effect in a chronic model of focal neocortical epilepsy. Chemical–genetic seizure attenuation holds promise as a novel approach to treat intractable focal epilepsy while minimizing disruption of normal circuit function in untransduced brain regions or in the absence of the specific ligand.

References 26

1. 1.
   Estimation of the burden of active and life‐time epilepsy: A meta‐analytic approach · 2010

   No notice
2. 2.

   Kwan P., Schachter S. C. & Brodie M. J. Drug-resistant epilepsy. N. Engl. J. Med. 365, 919–926 (2011 ).

   Not in our library10.1056/nejmra1004418

3. 3.

   Annegers J. F., Hauser W. A. & Elveback L. R. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20, 729–737 (1979 ).

   Not in our library10.1111/j.1528-1157.1979.tb04857.x

4. 4.

   Rosenow F. & Lüders H. Presurgical evaluation of epilepsy. Brain J. Neurol. 124, 1683–1700 (2001 ).

   Not in our library10.1093/brain/124.9.1683

5. 5.

   Schuele S. U. & Lüders H. O. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol. 7, 514–524 (2008 ).

   Not in our library10.1016/s1474-4422(08)70108-x

6. 6.

   De Tisi J. et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 378, 1388–1395 (2011 ).

   Not in our library10.1016/s0140-6736(11)60890-8

7. 7.

   Wykes R. C. et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci. Transl. Med. 4, 161ra152 (2012 ).

   Not in our library10.1126/scitranslmed.3004190

8. 8.

   Paz J. T. et al. Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat. Neurosci. 16, 64–70 (2013 ).

   Not in our library10.1038/nn.3269

9. 9.

   Krook-Magnuson E., Armstrong C., Oijala M. & Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun. 4, 1376 (2013 ).

   Not in our library10.1038/ncomms2376

10. 10.

    Pei Y., Rogan S. C., Yan F. & Roth B. L. Engineered GPCRs as tools to modulate signal transduction. Physiology (Bethesda) 23, 313–321 (2008 ).

    Not in our library10.1152/physiol.00025.2008

11. 11.

    Armbruster B. N., Li X., Pausch M. H., Herlitze S. & Roth B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. USA 104, 5163–5168 (2007 ).

    Not in our library10.1073/pnas.0700293104

12. 12.

    Ferguson S. M. et al. Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat. Neurosci. 14, 22–24 (2011 ).

    Not in our library10.1038/nn.2703

13. 13.

    Chang P., Hashemi K. S. & Walker M. C. A novel telemetry system for recording EEG in small animals. J. Neurosci. Methods 201, 106–115 (2011 ).

    Not in our library10.1016/j.jneumeth.2011.07.018

14. 14.

    Wulff P. & Arenkiel B. R. Chemical genetics: receptor-ligand pairs for rapid manipulation of neuronal activity. Curr. Opin. Neurobiol. 22, 54–60 (2012 ).

    Not in our library10.1016/j.conb.2011.10.008

15. 15.

    Louis E. D., Williamson P. D. & Darcey T. M. Chronic focal epilepsy induced by microinjection of tetanus toxin into the cat motor cortex. Electroencephalogr. Clin. Neurophysiol. 75, 548–557 (1990 ).

    Not in our library10.1016/0013-4694(90)90141-6

16. 16.

    Nilsen K. E., Walker M. C. & Cock H. R. Characterization of the tetanus toxin model of refractory focal neocortical epilepsy in the rat. Epilepsia 46, 179–187 (2005 ).

    Not in our library10.1111/j.0013-9580.2005.26004.x

17. 17.

    Cockerell O. C., Rothwell J., Thompson P. D., Marsden C. D. & Shorvon S. D. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain J. Neurol. 119, (Pt 2): 393–407 (1996 ).

    Not in our library10.1093/brain/119.2.393

18. 18.

    Garner A. R. et al. Generation of a synthetic memory trace. Science 335, 1513–1516 (2012 ).

    Not in our library10.1126/science.1214985

19. 19.

    Alexander G. M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27–39 (2009 ).

    Not in our library10.1016/j.neuron.2009.06.014

20. 20.

    Baldessarini R. J. et al. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9, 117–124 (1993 ).

    Not in our library10.1038/npp.1993.50

21. 21.

    Levey A. I., Edmunds S. M., Koliatsos V., Wiley R. G. & Heilman C. J. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J. Neurosci. 15, 4077–4092 (1995 ).

    Not in our library10.1523/jneurosci.15-05-04077.1995

22. 22.

    Shirey J. K. et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 4, 42–50 (2008 ).

    Not in our library10.1038/nchembio.2007.55

23. 23.

    Guitton C., Abbar M., Kinowski J. M., Chabrand P. & Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18, 470–476 (1998 ).

    Not in our library10.1097/00004714-199812000-00010

24. 24.

    Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7, 385–395 (2011 ).

    Not in our library10.1038/nrendo.2011.32

25. 25.

    Cook M. J. et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol. 12, 563–571 (2013 ).

    Not in our library10.1016/s1474-4422(13)70075-9

26. 26.

    Akam T., Oren I., Mantoan L., Ferenczi E. & Kullmann D. M. Oscillatory dynamics in the hippocampus support dentate gyrus–CA3 coupling. Nat. Neurosci. 15, 763–768 (2012 ).

    Not in our library10.1038/nn.3081

Cited by papers we hold 5

• In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy · 2020
  No notice
• Gene Therapy Tools for Brain Diseases · 2019
  No notice
• Chemogenetic Recruitment of Specific Interneurons Suppresses Seizure Activity · 2018
  Not checked
• Na v 1.7 and other voltage-gated sodium channels as drug targets for pain relief · 2016
  No notice
• Clozapine N-Oxide Administration Produces Behavioral Effects in Long–Evans Rats: Implications for Designing DREADD Experiments · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.